What Is Parkinson's Dementia?

Parkinson's disease dementia (PDD) is a feature of Parkinson's disease, a progressive movement disorder associated with both motor (movement-related) and nonmotor symptoms.

Dementia causes symptoms like difficulties with memory and making decisions and changes in behavior and mood. It can develop on average about 10 years after PD-related movement symptoms, namely stiffness, shaking, slow movements (bradykinesia), and loss of balance.

Approximately 20% to 40% of people currently living with PD have dementia, and up to 80% of people with PD will eventually develop it.

This article reviews the symptoms, diagnosis, risk factors, and treatment of Parkinson's disease dementia. It also helps distinguish PDD from dementia with Lewy bodies (DLB), a condition with overlapping biologies and symptoms.

An older couple sits on a bed talking

Jessie Casson / Getty Images

Symptoms of Parkinson’s Dementia

The symptoms of Parkinson's dementia are classified as either cognitive or behavioral.

Cognitive symptoms include:

  • Executive dysfunction involves difficulties in multitasking, problem-solving, and planning. For instance, a person may need help balancing a checkbook, following a recipe, or keeping their bedroom organized.
  • Visuospatial dysfunction is trouble processing information about three-dimensional (3D) objects (e.g., judging distances, leading to difficulty driving or parking).
  • Impaired attention is when a person has problems concentrating, like holding a conversation or reading a book.
  • Impaired verbal memory is when a person has trouble understanding complex sentences or has a problem finding words.

Behavioral symptoms include:

  • Apathy is a lack of interest, passion, or motivation for once engaged in or enjoyed activities. A person may stop pursuing hobbies or following their medication schedule.
  • Delusions are when a person believes something to be true when it's not. In PDD, delusions are usually paranoid—for example, a person may accuse family members of stealing their money or falsely accuse their partner of infidelity.
  • Sleep disorders, namely excessive daytime sleepiness or rapid eye movement (REM) sleep behavior disorder, occur in PDD. In the latter condition, a person physically acts out their dreams, potentially causing harm to themselves or their bed partner.
  • Visual hallucinations are when a person sees something that is not there, like an animal or person.

Parkinson’s Dementia and Hallucinations

Visual hallucinations are the most common type of hallucination in Parkinson's dementia. Most are complex, in which a person sees vivid images, such as animals, faces, objects, or scenery, that are often familiar, lifelike, and not frightening.

In some instances, visual hallucinations are simple. A person may see moving dots, shapes, patterns, colors, or illusions of objects passing across the periphery of their vision.

Less commonly, auditory (hearing) hallucinations may occur in Parkinson's disease, such as hearing muffled sounds.

Olfactory (smell), gustatory (taste), and tactile (feel) hallucinations also develop on occasion, although, if present, they tend to coexist with visual hallucinations.

Confounding the picture is that some drugs used to treat Parkinson's disease can aggravate visual hallucinations. These drugs include:

How Is Parkinson’s Dementia Diagnosed?

No single blood or imaging test on its own can diagnose Parkinson's dementia. Instead, the diagnosis is clinical, based on a person's medical history, symptoms, and physical examination.

A neurologist, especially one specializing in movement disorders, makes the diagnosis, often using criteria set forth by the International Parkinson and Movement Disorder Society (MDS).

Core features of the criteria include that a person has:

  • An established diagnosis of Parkinson's disease
  • Symptoms of dementia that started gradually and have slowly worsened over time
  • Impairment in at least two cognitive domains (e.g., attention, executive function, visual-spatial ability, memory)
  • Cognitive deficiency is severe enough to impair daily life—social, occupation, or personal care—independent of impairment because of motor symptoms

Interestingly, behavioral symptoms are supportive of a diagnosis of Parkinson's dementia but are not required.

Lastly, before confirming a diagnosis of Parkinson's dementia, other explanations for cognitive problems must be ruled out, such as stroke, depression, or a medication side effect.

What Causes Parkinson’s Dementia?

The development and spread of Lewy bodies (sticky clumps of the protein alpha-synuclein) throughout the brain is linked to the development of Parkinson's dementia.

These Lewy bodies are believed to impair the functioning of multiple chemical messaging systems within the brain, ultimately leading to the death of nerve cells that produce dopamine.

It's unclear exactly why or how these Lewy bodies form, although genetic, aging, and environmental factors (e.g., exposures to specific pesticides or metals) are likely involved.

Keep in mind that while brain damage in Parkinson's dementia is primarily due to Lewy body formation, abnormal accumulation of two other proteins—amyloid and tau—are also believed to contribute. These two proteins are linked to Alzheimer's disease.

Parkinson's vs. Alzheimer's

Parkinson's disease and Alzheimer's disease are progressive brain disorders that result in nerve cell death. However, Parkinson's is primarily a movement disorder that can sometimes cause dementia, whereas Alzheimer's disease always causes dementia.

Risk Factors for Developing Parkinson’s Dementia

Risk factors for Parkinson's dementia are increasing age, longer disease duration, a more severe disease course, and older age at disease onset.

In addition, some early disease symptoms are linked to an increased risk of Parkinson's dementia. These include the presence of:

  • Orthostatic hypotension (a sudden lowering of blood pressure when a person stands up)
  • Rapid eye movement behavior disorder (RBD)
  • Hyposmia (reduced sense of smell)
  • Postural instability (difficulty balancing) and gait dysfunction (e.g., small, shuffling steps and reduced arm swing)
  • Visual hallucinations and dysfunction (e.g., inability to discriminate among colors)

Lastly, specific genetic markers—for example, the presence of the APOE-ε4 gene—and cerebrospinal fluid findings (e.g., a low amount of Aβ1-42) also predict an increased risk for Parkinson's disease.

Side Note

The presence of the APOE-ε4 gene is also a risk factor for Alzheimer's disease. Aβ1-42 is the major component of amyloid collections seen in the brains of people with Alzheimer's disease.

How Is Parkinson’s Dementia Treated?

There is no cure for Parkinson's disease dementia; however, various therapies can ease symptoms to improve daily functioning and quality of life.

Medications for Parkinson's dementia include:

  • Cholinesterase inhibitors help with thinking/memory problems and include Aricept (donepezil), Exelon (rivastigmine), and Razadyne (galantamine).
  • Melatonin supplements help manage sleep problems.
  • The antipsychotic Clozaril (clozapine) helps manage hallucinations and delusions.

Non-drug therapies for PDD include cognitive rehabilitation, exercise, physical therapy, music therapy, and art therapy.

Lewy Body Dementia vs. Parkinson’s Disease Dementia

Like PDD, dementia with Lewy bodies (DLB) is a progressive, neurodegenerative condition associated with the buildup of Lewy bodies within the brain.

These complex diseases share various motor, cognitive, and behavioral characteristics, such as stiffness, slow movements, visual-spatial dysfunction, and visual hallucinations.

That said, a critical distinguishing feature is that Parkinson's disease dementia occurs at least one year—but usually several years—after the onset of motor symptoms.

On the other hand, in DLB, dementia symptoms occur before or around the same time as the development of motor symptoms.

Other distinguishing features are:

  • In DLB, there is an overall faster cognitive decline compared to Parkinson's disease dementia.
  • Motor function appears to improve more in people with Parkinson’s disease dementia taking levodopa (a drug that increases dopamine levels) than in those with DLB.

End-Stage Parkinson’s Dementia

Severe, debilitating symptoms mark end-stage Parkinson's dementia. Worsening sleep problems and frequent hallucinations tend to occur, and individuals can become extremely confused, depressed, anxious, or hostile.

Besides symptoms of dementia, motor symptoms, such as frequent freezing episodes (when they suddenly cannot move), prevent people from being able to walk or stand on their own.

Severe constipation, significant difficulty with speaking and swallowing, and complications like falls, malnutrition, dehydration, and weight loss are also common at the end stages of the disease.

Outlook for Someone With Parkinson’s Disease Dementia

People with Parkinson's disease dementia are at a higher risk of dying compared to the general population and to those with Parkinson's disease without dementia.

In fact, some research suggests that a person with PDD lives an average of five to seven years. That said, there is no surefire way to predict the outlook for or life expectancy of any person with PDD, as it can vary considerably.

The best thing you can do if you or a loved one has Parkinson's disease dementia is focus your energy on facets of life and of the disease you can control, such as staying hydrated, eating nutritiously, and engaging in physical activity (if possible).

Also, keep in close contact with your healthcare team, take your medication as prescribed, and reach out to loved ones, neighbors, or a support group for comfort and social connection.

When to Contact a Healthcare Provider

If you are experiencing thinking, memory, or behavior problems (whether or not you have been diagnosed with Parkinson's disease), please make an appointment with a healthcare provider.

They can assess you for all possible causes of your cognitive/ behavioral concerns and refer you to a neurologist for additional diagnostic tests if deemed appropriate.

Summary

Parkinson's disease dementia is a progressive condition caused by the accumulation of Lewy bodies (clumps of alpha-synuclein protein) in the brain, resulting in the death of dopamine-producing nerve cells.

Symptoms of PDD include problems planning and concentrating, recognizing faces, and seeing or believing things that aren't real (hallucinations and delusions). Sleep and mood problems like apathy (lack of motivation) are also common.

Unlike the related condition—dementia with Lewy bodies—PDD develops at least one year but usually several years after the onset of motor (movement-related) symptoms like stiffness and shaking.

Treatment of PDD aims at reducing symptoms and often includes a combination of medication and nondrug therapies like cognitive rehabilitation and exercise.

23 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. UCSF Memory and Aging Center. Parkinson's disease dementia.

  2. Åström DO, Simonsen J, Raket LL, et al. High risk of developing dementia in Parkinson's disease: a Swedish registry-based study. Sci Rep. 2022;12(1):16759. doi:10.1038/s41598-022-21093-8

  3. Hanagasi HA, Tufekcioglu Z, Emre M. Dementia in Parkinson's disease. J Neurol Sci. 2017;374:26-31. doi:10.1016/j.jns.2017.01.012

  4. Aarsland D, Taylor JP, Weintraub D. Psychiatric issues in cognitive impairment. Mov Disord. 2014;29(5):651-62. doi:10.1002/mds.25873

  5. Maggi G, Trojano L, Barone P, Santangelo G. Sleep disorders and cognitive dysfunctions in Parkinson's disease: a meta-analytic study. Neuropsychol Rev. 2021;31(4):643-682. doi:10.1007/s11065-020-09473-1

  6. Weil RS, Reeves S. Hallucinations in Parkinson's disease: new insights into mechanisms and treatments. Adv Clin Neurosci Rehabil. 2020;19(4):ONNS5189. doi:10.47795/ONNS5189

  7. Vasconcellos LF, Pereira JS. Parkinson's disease dementia: diagnostic criteria and risk factor review. J Clin Exp Neuropsychol. 2015;37(9):988-93. doi:10.1080/13803395.2015.1073227

  8. Koros C, Stefanis L, Scarmeas N. Parkinsonism and dementiaJ Neurol Sci. 2022;433:120015. doi:10.1016/j.jns.2021.120015

  9. De Miranda BR, Goldman SM, Miller GW, Greenamyre JT, Dorsey ER. Preventing Parkinson's disease: an environmental agendaJ Parkinsons Dis. 2022;12(1):45-68. doi:10.3233/JPD-212922

  10. Hussain MW, Camicioli R. Nonmotor symptoms of Parkinson's disease as predictors of dementia. Can J Neurol Sci. 2018;45(1):97-99. doi:10.1017/cjn.2017.239

  11. Schrag A, Siddiqui UF, Anastasiou Z, Weintraub D, Schott JM. Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study. Lancet Neurol. 2017;16(1):66-75. doi: 0.1016/S1474-4422(16)30328-3

  12. Zarkali A, McColgan P, Ryten M, et al. Dementia risk in Parkinson's disease is associated with interhemispheric connectivity loss and determined by regional gene expression. Neuroimage Clin. 2020;28:102470. doi:10.1016/j.nicl.2020.102470

  13. Lim EW, Aarsland D, Ffytche D, et al. Amyloid-β and Parkinson's disease. J Neurol. 2019;266(11):2605-2619. doi:10.1007/s00415-018-9100-8

  14. Fyfe I. APOE*ε4 promotes synucleinopathy. Nat Rev Neurol. 2020;16(4):185. doi:10.1038/s41582-020-0335-5

  15. Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a reviewJAMA. 2020;323(6):548-560. doi:10.1001/jama.2019.22360

  16. Wang HF, Yu JT, Tang SW, et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry. 2015;86(2):135-43. doi:10.1136/jnnp-2014-307659

  17. Tamtaji OR, Reiter RJ, Alipoor R, Dadgostar E, Kouchaki E, Asemi Z. Melatonin and Parkinson Disease: Current Status and Future Perspectives for Molecular Mechanisms. Cell Mol Neurobiol. 2020 Jan;40(1):15-23. doi:10.1007/s10571-019-00720-5

  18. Goldman JG, Holden S. Treatment of psychosis and dementia in Parkinson's disease. Curr Treat Options Neurol. 2014 Mar;16(3):281. doi:10.1007/s11940-013-0281-2

  19. Jellinger KA. Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies. J Neural Transm (Vienna). 2018;125(4):615-650. doi:10.1007/s00702-017-1821-9

  20. Utsumi K, Fukatsu R, Hara Y, Takamaru Y, Yasumura S. Psychotic features among patients in the prodromal stage of dementia with Lewy bodies during longitudinal observation. J Alzheimers Dis. 2021;83(4):1917-1927. doi:10.3233/JAD-210416

  21. Taylor JP, McKeith IG, Burn DJ, et al. New evidence on the management of Lewy body dementia. Lancet Neurol. 2020;19(2):157-169. doi:10.1016/S1474-4422(19)30153-X

  22. Luquin M-R, Kulisevsky J, Martinez-Martin P, Mir P, Tolosa ES. Consensus on the definition of advanced Parkinson's disease: a neurologists-based Delphi study (CEPA Study)Parkinsons Dis. 2017;2017:4047392. doi:10.1155/2017/4047392

  23. Savica R, Grossardt BR, Bower JH, et al. Survival and causes of death among people with clinically diagnosed synucleinopathies with parkinsonism: a population-based study. JAMA Neurol. 2017;74(7):839-846. doi:10.1001/jamaneurol.2017.0603

Colleen Doherty, MD

By Colleen Doherty, MD
Dr. Doherty is a board-certified internist and writer living with multiple sclerosis. She is based in Chicago.